Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica

Universidad de Costa Rica25 enrolled

Overview

The use of circulating tumor DNA (ctDNA) as a noninvasive test for breast cancer monitoring throughout the course of the disease

The concentrations of the cell free DNA (cfDNA) and somatic mutations in circulating tumor DNA (ctDNA) in serial samples correlate with the number of days of the progression-free period and with the overall survival.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastatic Breast Cancer Mutation, Point

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Metastatic breast cancer before the start of chemotherapeutic treatment Exclusion Criteria: * Patients with incomplete clinical records

Locations (1)

Hospital San Juan de Dios

San José, Costa Rica

RECRUITING

Outcomes

Primary Outcomes

Assessment of circulating free DNA (cfDNA) concentration (in ng/uL) obtained from peripheral blood (liquid biopsy).

Samples will be analyze with Real time PCR and fluorometric assay and compare with overall survival

Time frame: 12 months

Number of somatic mutation findings in circulating free DNA (cfDNA) obtained from peripheral blood (liquid biopsy)

Samples will be analyze with targeted NGS sequencing panel

Time frame: 12 months

Secondary Outcomes

Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2) status

ER, PR, HER2 status

Time frame: 24 months

Overall survival of participant

Time frame: 24 months

Cancer stage of participant

Time frame: 24 months

Central Contacts

Ricardo Chinchilla

CONTACT

+50625113483 ricardo.chinchilla_m@ucr.ac.cr

Allan Ramos, Msc.

CONTACT

+50688448187 allan.ramos@ucr.ac.cr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.